Wong, YNS;
Sng, CCT;
Ottaviani, D;
Patel, G;
Chowdhury, A;
Earnshaw, I;
Sinclair, A;
... Lee, AJX; + view all
(2021)
Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two uk waves of the covid-19 pandemic at university college london hospital.
Cancers
, 13
(23)
, Article 6085. 10.3390/cancers13236085.
Preview |
Text
Lee_cancers-13-06085.pdf - Published Version Download (1MB) | Preview |
Abstract
An increased mortality risk was observed in patients with cancer during the first wave of COVID-19. Here, we describe determinants of mortality in patients with solid cancer comparing the first and second waves of COVID-19. A retrospective analysis encompassing two waves of COVID-19 (March–May 2020; December 2020–February 2021) was performed. 207 patients with cancer were matched to 452 patients without cancer. Patient demographics and oncological variables such as cancer subtype, staging and anti-cancer treatment were evaluated for association with COVID-19 mortality. Overall mortality was lower in wave two compared to wave one, HR 0.41 (95% CI: 0.30–0.56). In patients with cancer, mortality was 43.6% in wave one and 15.9% in wave two. In hospitalized patients, after adjusting for age, ethnicity and co-morbidities, a history of cancer was associated with increased mortality in wave one but not wave two. In summary, the second UK wave of COVID-19 is associated with lower mortality in hospitalized patients. A history of solid cancer was not associated with increased mortality despite the dominance of the more transmissible B.1.1.7 SARS-CoV-2 variant. In both waves, metastatic disease and systemic anti-cancer treatment appeared to be independent risk factors for death within the combined cancer cohort.
| Type: | Article |
|---|---|
| Title: | Systemic anti-cancer therapy and metastatic cancer are independent mortality risk factors during two uk waves of the covid-19 pandemic at university college london hospital |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.3390/cancers13236085 |
| Publisher version: | https://doi.org/10.3390/cancers13236085 |
| Language: | English |
| Additional information: | This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | COVID-19; SARS-CoV-2 infection; solid cancer; risk factors; systemic anti-cancer therapy; co-morbidity; second wave; alpha variant; B.1.1.7 |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > CRUK Cancer Trials Centre UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10139936 |
Archive Staff Only
 |
View Item |
